There’s a reason that venture firms in Boston love building their own companies: It helps to have a hand-picked leader with a proven track record at the helm of an early-stage biotech company.
Waltham, Mass.-based Skyhawk Therapeutics is bucking that trend with gusto. In June 2018, the company announced a $100 million early-stage venture fundraising round and partnership deals with Biogen (BIIB) and Celgene (CELGZ) (which was just acquired by Bristol-Myers Squibb for $74 billion). Earlier this month, the company was at the annual J.P. Morgan Healthcare Conference looking for more. Yet their chief executive officer, Bill Haney, has less than five years of experience as a biotech executive; his only other biotech company is Dragonfly Therapeutics.